Evolution of Islet Transplantation for the Last 30 Years

Pancreas

Volumn 45, Issue 1, 2016, Pages 8-20

  Farney, Alan C ^a   Sutherland, David E R ^b   Opara, Emmanuel C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

diabetes; islet isolation; microencapsulation; transplantation

Indexed keywords

ALGINIC ACID; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; IMMUNOSUPPRESSIVE AGENT; INSULIN;

CELL ENCAPSULATION; CELL ISOLATION; CELL SURVIVAL; CELL TRACKING; HORMONE SUBSTITUTION; HUMAN; INSULIN TREATMENT; MICROCAPSULE; MICROENCAPSULATION; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SCALE UP; ADVERSE EFFECTS; ANIMAL; BLOOD; CONVALESCENCE; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HISTORY; MASS COMMUNICATION; METABOLISM; PANCREAS ISLET; PATHOPHYSIOLOGY; TREATMENT OUTCOME; TRENDS;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; DIFFUSION OF INNOVATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 84952705670     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000391     Document Type: Review

References (147)

1. Bliss M,. The Discovery of Insulin. Chicago: The University of Chicago Press; 1982.
2. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996; 45: 1289-1298.
3. Hampton T,. Fully automated artificial pancreas finally within reach. JAMA. 2014; 311: 2260-2261.
4. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997; 46: 271-286.
5. Kelly WD, Lillehei RC, Merkel FK, Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967; 61: 827-837.
6. SRTR. In: Services USDoHaH, ed. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 2002-2011. Rockville, MD: Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
7. Sutherland DE, Goetz FC, Rynasiewicz JJ, Segmental pancreas transplantation from living related and cadaver donors: a clinical experience. Surgery. 1981; 90: 159-169.
8. Farney AC, Rogers J, Stratta RJ,. Pancreas graft thrombosis: causes, prevention, diagnosis, and intervention. Curr Opin Organ Transplant. 2012; 17: 87-92.
9. Sutherland DE, Goetz FC, Sibley RK,. Recurrence of disease in pancreas transplants. Diabetes. 1989; 38 (suppl 1): 85-87.
10. Stratta RJ, Farney AC, Rogers J, Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective. Expert Rev Clin Immunol. 2014; 10: 117-132.
11. Selawry HP, Whittington K,. Extended allograft survival of islets grafted into intra-abdominally placed testis. Diabetes. 1984; 33: 405-406.
12. Ballinger WF, Lacy PE,. Transplantation of intact pancreatic islets in rats. Surgery. 1972; 72: 175-186.
13. Okitsu T, Bartlett ST, Hadley GA, Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice. Am J Transplant. 2001; 1: 138-145.
14. Kemp CB, Knight MJ, Scharp DW, Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia. 1973; 9: 486-491.
15. Kemp CB, Knight MJ, Scharp DW, Transplantation of isolated pancreatic islets into the portal vein of diabetic rats. Nature. 1973; 244: 447.
16. Posselt AM, Barker CF, Tomaszewski JE, Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science. 1990; 249: 1293-1295.
17. Gray DW, Reece-Smith H, Fairbrother B, Isolated pancreatic islet allografts in rats rendered immunologically unresponsive to renal allografts. The effect of the site of transplantation. Transplantation. 1984; 37: 434-437.
18. London NJ, Donnelly PK,. Techniques of pancreas and islet transplantation. Baillieres Clin Gastroenterol. 1994; 8: 517-532.
19. Serup P, Madsen OD, Mandrup-Poulsen T,. Islet and stem cell transplantation for treating diabetes. BMJ. 2001; 322: 29-32.
20. Memsic L, Busuttil RW, Traverso LW,. Bleeding esophageal varices and portal vein thrombosis after pancreatic mixed-cell autotransplantation. Surgery. 1984; 95: 238-242.
21. Toledo-Pereyra LH, Rowlett AL, Cain W, Hepatic infarction following intraportal islet cell autotransplantation after near-total pancreatectomy. Transplantation. 1984; 38: 88-89.
22. Balamurugan AN, Breite AG, Anazawa T, Successful human islet isolation and transplantation indicating the importance of class 1 collagenase and collagen degradation activity assay. Transplantation. 2010; 89: 954-961.
23. Campbell-Thompson ML, Heiple T, Montgomery E, Staining protocols for human pancreatic islets. J Vis Exp. 2012; 63: e4068.
24. Alejandro R, Barton FB, Hering BJ, 2008 Update from the Collaborative Islet Transplant Registry. Transplantation. 2008; 86: 1783-1788.
25. Hering B, Bridges N, Eggerman T, Phase 3 trial of transplantation of human islets in Type 1 diabetes (T1D) complicated by severe hypoglycemia. 74th Scientific Sessions American Diabetes Association; June 17, 2014; San Francisco.
26. Moskalewski S,. Isolation and culture of the islets of Langerhans of the guinea pig. Gen Comp Endocrinol. 1965; 5: 342-353.
27. Lacy PE, Kostianovsky M,. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes. 1967; 16: 35-39.
28. Scharp DW, Kemp CB, Knight MJ, The use of ficoll in the preparation of viable islets of langerhans from the rat pancreas. Transplantation. 1973; 16: 686-689.
29. Mirkovitch V, Campiche M,. Successful intrasplenic autotransplantation of pancreatic tissue in totally pancreatectomised dogs. Transplantation. 1976; 21: 265-269.
30. Alejandro R, Cutfield R, Shienvold FL, Successful long-term survival of pancreatic islet allografts in spontaneous or pancreatectomy-induced diabetes in dogs. Cyclosporine-induced immune unresponsiveness. Diabetes. 1985; 34: 825-828.
31. Kretschmer GJ, Sutherland DE, Matas AJ, Autotransplantation of pancreatic islets without separation of exocrine and endocrine tissue in totally pancreatectomized dogs. Surgery. 1977; 82: 74-81.
32. Sutherland DE, Matas AJ, Goetz FC, Transplantation of dispersed pancreatic islet tissue in humans: autografts and allografts. Diabetes. 1980; 29 (suppl 1): 31-44.
33. Gray DW, McShane P, Grant A, A method for isolation of islets of Langerhans from the human pancreas. Diabetes. 1984; 33: 1055-1061.
34. Toledo-Pereyra LH, Rowlett AL, Lodish M,. Autotransplantation of pancreatic islet cell fragments into the renal capsule prepared without collagenase. Am Surg. 1984; 50: 679-681.
35. Tze WJ, Tai J,. Successful intracerebral allotransplantation of pancreatic endocrine cells in spontaneous diabetic BB rats without immunosuppression. Metabolism. 1984; 33: 785-789.
36. Tze WJ, Tai J,. Intracerebral allotransplantation of purified pancreatic endocrine cells and pancreatic islets in diabetic rats. Transplantation. 1984; 38: 107-111.
37. Zastrow F,. Isolation of islet cell transplants and their efficiency in various host organs. Fortschr Med. 1984; 102: 434-436.
38. Altman JJ, Houlbert D, Chollier A, Encapsulated human islet transplants in diabetic rats. Trans Am Soc Artif Intern Organs. 1984; 30: 382-386.
39. O'Shea GM, Goosen MF, Sun AM,. Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane. Biochim Biophys Acta. 1984; 804: 133-136.
40. Sun AM, O'Shea GM, Goosen MF,. Injectable microencapsulated islet cells as a bioartificial pancreas. Appl Biochem Biotechnol. 1984; 10: 87-99.
41. Charles MA, Sharma B, Dodson LE Jr, Mechanisms of rat pancreatic islet allograft rejection. Diabetes Res. 1984; 1: 95-103.
42. Faustman DL, Steinman RM, Gebel HM, Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc Natl Acad Sci U S A. 1984; 81: 3864-3868.
43. Hardy MA, Lau H, Weber C, Pancreatic islet transplantation. Induction of graft acceptance by ultraviolet irradiation of donor tissue. Ann Surg. 1984; 200: 441-450.
44. Hegre OD, Hickey GE, Marshall S, Modification of allograft immunogenicity in perinatal islets isolated and purified in vitro. Transplantation. 1984; 37: 227-233.
45. Nash JR, Bell PR,. Islet transplantation-synergism between antilymphocyte and antimacrophage agents. J Surg Res. 1984; 36: 154-157.
46. Warren HS, Prowse SJ, Agostino M, Lyt-2+ cells sensitized to graft alloantigens trigger the rejection of established cultured pancreatic islet allografts. Transplant Proc. 1984; 16: 954-955.
47. Weber C, Ting W, Rosenkrantz K, Islet transplantation in autoimmune diabetes mellitus. Transplant Proc. 1984; 16: 845-848.
48. Nishino H, Ohkita H, Fukamizu A, Prolongation of survival time of rat pancreatic islet allografts by tissue culture. Transplant Proc. 1984; 16: 1687-1693.
49. du Toit DF, Heydenrych JJ, Smit B, Experimental vascularized segmental pancreatic and islet transplantation in the baboon. World J Surg. 1984; 8: 236-243.
50. Lau H, Reemtsma K, Hardy MA,. Prolongation of rat islet allograft survival by direct ultraviolet irradiation of the graft. Science. 1984; 223: 607-609.
51. Lau H, Reemtsma K, Hardy MA,. The use of direct ultraviolet irradiation and cyclosporine in facilitating indefinite pancreatic islet allograft acceptance. Transplantation. 1984; 38: 566-569.
52. Sutherland DE, Goetz FC, Chinn PL, Pancreas transplantation. Pediatr Clin North Am. 1984; 31: 735-750.
53. Scharp DW, Murphy JJ, Newton WT, Transplantation of islets of Langerhans in diabetic rhesus monkeys. Surgery. 1975; 77: 100-105.
54. Ricordi C, Lacy PE, Finke EH, Automated method for the isolation of human pancreatic islets. Diabetes. 1988; 37: 413-420.
55. Ricordi C, Finke EH, Lacy PE,. A method for the mass isolation of islets from the adult pig pancreas. Diabetes. 1986; 35: 649-653.
56. Hansen WA, Christie MR, Kahn R, Supravital dithizone staining in the isolation of human and rat pancreatic islets. Diabetes Res. 1989; 10: 53-57.
57. Latif ZA, Noel J, Alejandro R,. A simple method of staining fresh and cultured islets. Transplantation. 1988; 45: 827-830.
58. Kissler HJ, Niland JC, Olack B, Validation of methodologies for quantifying isolated human islets: an Islet Cell Resources study. Clin Transplant. 2010; 24: 236-242.
59. London NJ, Contractor H, Lake SP, A fluorometric viability assay for single human and rat islets. Horm Metab Res Suppl. 1990; 25: 82-87.
60. London NJ, Robertson GS, Chadwick DR, Human pancreatic islet isolation and transplantation. Clin Transplant. 1994; 8: 421-459.
61. Luzi L, Socci C, Falqui L, Successful intraportal islet transplantation reverses non-steroid-related insulin resistance in humans. Transplant Proc. 1994; 26: 572.
62. Mazzaferro V, Socci C, Regalia E, Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression. Transpl Int. 1994; 7 (suppl 1): S409-S411.
63. Ricordi C, Rilo HL, Carroll PB, Human islet allograft follow-up: long-term islet function and over 3 years of insulin independence. Transplant Proc. 1994; 26: 569.
64. Scharp DW,. Clinical feasibility of islet transplantation. Transplant Proc. 1984; 16: 820-825.
65. Scharp DW, Lacy PE, Santiago JV, Insulin independence after islet transplantation into type I diabetic patient. Diabetes. 1990; 39: 515-518.
66. Gores PF, Najarian JS, Stephanian E, Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet. 1993; 341: 19-21.
67. Ricordi C, Tzakis AG, Carroll PB, Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation. 1992; 53: 407-414.
68. Sutherland DE, Gores PF, Farney AC, Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the University of Minnesota. Am J Surg. 1993; 166: 456-491.
69. Sutherland DE,. Pancreas and islet transplantation. II. Clinical trials. Diabetologia. 1981; 20: 435-450.
70. Hering B, Brendel M, Schultz A, International Islet Transplant Registry Newsletter No. 7. Giessen: University of Giessen; 1996.
71. Gotoh M, Maki T, Porter J, Augmented survival of purified islet xeno- and allografts with reduced numbers. Transplant Proc. 1987; 19: 984.
72. Drachenberg CB, Klassen DK, Weir MR, Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999; 68: 396-402.
73. Herold KC, Nagamatsu S, Buse JB, Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation. 1993; 55: 186-192.
74. Basadonna G, Montorsi F, Kakizaki K, Cyclosporin A and islet function. Am J Surg. 1988; 156: 191-193.
75. Bending JJ, Ogg CS, Viberti GC,. Diabetogenic effect of cyclosporin. Br Med J (Clin Res Ed). 1987; 294: 401-402.
76. Morel P, Kaufman DB, Field MJ, Detrimental effect of prednisone on canine islet autograft function. Transplant Proc. 1992; 24: 1048-1050.
77. Shapiro AM, Lakey JR, Ryan EA, Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000; 343: 230-238.
78. Ryan EA, Lakey JR, Rajotte RV, Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes. 2001; 50: 710-719.
79. Shapiro AM, Ricordi C, Hering BJ, International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006; 355: 1318-1330.
80. Ichii H, Ricordi C,. Current status of islet cell transplantation. J Hepatobiliary Pancreat Surg. 2009; 16: 101-112.
81. Kessler L, Parissiadis A, Bayle F, Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant. 2009; 1961-1966.
82. Mohanakumar T, Narayanan K, Desai N, A significant role for histocompatibility in human islet transplantation. Transplantation. 2006; 82: 180-187.
83. Piemonti L, Everly MJ, Maffi P, Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes. 2013; 62: 1656-1664.
84. Rickels MR, Kamoun M, Kearns J, Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity. J Clin Endocrinol Metab. 2007; 92: 2410-2414.
85. Farney AC, Najarian JS, Nakhleh RE, Autotransplantation of dispersed pancreatic islet tissue combined with total or near-total pancreatectomy for treatment of chronic pancreatitis. Surgery. 1991; 110: 427-437.
86. Bellin MD, Kandaswamy R, Parkey J, Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant. 2008; 8: 2463-2470.
87. Posselt AM, Bellin MD, Tavakol M, Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010; 10: 1870-1880.
88. Barton FB, Rickels MR, Alejandro R, Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 2012; 35: 1436-1445.
89. Pagliuca FW, Millman JR, Gurtler M, Generation of functional human pancreatic β cells in vitro. Cell. 2014; 159: 428-439.
90. Kizilel S, Garfinkel M, Opara E,. The bioartificial pancreas: progress and challenges. Diabetes Technol Ther. 2005; 7: 968-985.
91. Jain K, Asina S, Yang H, Glucose control and long-term survival in biobreeding/worcester rats after intraperitoneal implantation of hydrophilic macrobeads containing porcine islets without immunosuppression. Transplantation. 1999; 68: 1693-1700.
92. Opara EC, Mirmalek-Sani SH, Khanna O, Design of a bioartificial pancreas. J Investig Med. 2010; 58: 831-837.
93. O'Sullivan ES, Vegas A, Anderson DG, Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain. Endocr Rev. 2011; 32: 827-844.
94. Pareta RA, McQuilling JP, Farney A, Bioartificial pancreas: evaluation of crucial barriers to clinical application. In: Randhawa G, ed. Organ Donation and Transplantation-Public Policy and Clinical Perspectives. Rijeka, Croatia: INTECH Publishers; 2012: 241-266.
95. Scharp DW, Marchetti P,. Encapsulated islets for diabetes therapy: history, current progress, and critical issues requiring solution. Adv Drug Deliv Rev. 2014; 67-68: 35-73.
96. van Suylichem PT, Strubbe JH, Houwing H, Insulin secretion by rat islet isografts of a defined endocrine volume after transplantation to three different sites. Diabetologia. 1992; 35: 917-923.
97. De Vos P, Marchetti P,. Encapsulation of pancreatic islets for transplantation in diabetes: the untouchable islets. Trends Mol Med. 2002: 363-366.
98. Lim F, Sun AM,. Microencapsulated islets as bioartificial endocrine pancreas. Science. 1980; 210: 908-910.
99. Hill RS, Cruise GM, Hager SR, Immunoisolation of adult porcine islets for the treatment of diabetes mellitus: The use of photopolymerizable polyethylene glycol in the conformal coating of mass-isolated porcine islets. Ann N Y Acad Sci. 1997; 831: 332-343.
100. Teramura Y, Iwata H,. Islet encapsulation with living cells for improvement of biocompatibility. Biomaterials. 2009; 30: 2270-2275.
101. Donati I, Holtan S, Mørch YA, New hypothesis on the role of alternating sequences in calcium-alginate gels. Biomacromolecules. 2005; 6: 1031-1040.
102. Sandler S, Andersson A, Eizirik DL, Assessment of Insulin secretion in vitro from microencapsulated fetal porcine islet-like cell clusters and rat, mouse, and human pancreatic islets. Transplantation. 1997; 63: 1712-1718.
103. Lanza RP, Kuhtreiber WM, Ecker D, Xenotransplantation of porcine and bovine islets without immunosuppression using uncoated alginate microspheres. Transplantation. 1995; 59: 1377-1384.
104. van Schilfgaarde R, de Vos P,. Factors influencing the properties and performance of microcapsules for immunoprotection of pancreatic islets. J Mol Med (Berl). 1999; 77: 199-205.
105. Uludag H, De Vos P, Tresco PA,. Technology of mammalian cell encapsulation. Adv Drug Deliv Rev. 2000; 42: 29-64.
106. Darrabie M, Freeman BK, Kendall WF Jr, Durability of sodium sulfate-treated polylysine-alginate microcapsules. J Biomed Mater Res. 2001; 54: 396-399.
107. Darrabie MD, Kendall WF Jr, Opara EC,. Characteristics of Poly-L-Ornithine-coated alginate microcapsules. Biomaterials. 2005; 26: 6846-6852.
108. Tam SK, Bilodeau S, Dusseault J, Biocompatibility and physicochemical characteristics of alginate-polycation microcapsules. Acta Biomater. 2011; 7: 1683-1692.
109. Kulseng B, Thu B, Espevik T, Alginate polylysine microcapsules as immune barrier: permeability of cytokines and immunoglobulins over the capsule membrane. Cell Tranplant. 1997; 6: 387-394.
110. Strand BL, Ryan TL, In'1t Veld P, Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant. 2001; 10: 263-275.
111. Piro S, Lupi R, Dotta F, Bovine islets are less susceptible than human islets to damage by human cytokines. Transplantation. 2001; 71: 21-26.
112. Tendulkar S, Ramasubramanian MK, Opara EC,. Microencapsulation: the emerging role of microfluidics. Micro and Nanosystems. 2013; 5: 194-208.
113. Opara EC, Harrison BS,. The bioartificial pancreas-how should we address the issue of oxygen delivery? JSM Regen Med Bio Eng. 2013; 1: 1001.
114. Wendt D, Stroebel S, Jakob M, Uniform tissues engineered by seeding and culturing cells in 3D scaffolds under perfusion at defined oxygen tensions. Biorheology. 2006; 43: 481-488.
115. Li RH, Altreuter DH, Gentile FT,. Transport characterization of hydrogel matrices for cell encapsulation. Biotechnol Bioeng. 1996; 50: 365-373.
116. Chin K, Khattak SF, Bhatia SR, Hydrogel-perfluorocarbon composite scaffold promotes oxygen transport to immobilized cells. Biotechnol Prog. 2008; 24: 358-366.
117. Pareta R, McQuilling JP, Sivanandane S, Long-term function of islets encapsulated in a redesigned alginate microcapsule construct in omentum pouches of immune-competent diabetic rats. Pancreas. 2014; 43: 605-613.
118. Ludwig B, Rotem A, Schmid J, Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone agonist. Proc Natl Acad Sci U S A. 2012; 109: 5022-5027.
119. Dufrane D, Steenberghe MV, Goebbels RM, The influence of implantation site on the biocompatibility and survival of alginate encapsulated pig islets in rats. Biomaterials. 2006; 27: 3201-3208.
120. De Vos P, Van Straaten JF, Nieuwenhuizen AG, Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth? Diabetes. 1999; 48: 1381-1388.
121. Wilson JT, Chaikof EL,. Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv Drug Deliv Rev. 2008; 60: 124-145.
122. Barnett BP, Kraitchman DL, Lauzon C, Radiopaque alginate microcapsules for X-ray visualization and immunoprotection of cellular therapeutics. Mol Pharm. 2006; 3: 531-538.
123. Tiernan AR, Samabanis A,. Bioluminescence tracking of alginate microencapsulated cell transplants. J Tissue Eng Regen Med. 2014. doi: 10.1002/term.1946. [Epub ahead of print].
124. De Vos P, De Haan B, Wolters GH, Factors influencing the adequacy of microencapsulation of rat pancreatic islets. Transplantation. 1996; 62: 888-893.
125. de Vos P, de Haan B, de Haan A, Factors influencing functional survival of microencapsulated islet grafts. Cell Transplant. 2004; 13: 515-524.
126. Wolters GH, Fritschy WM, Gerrits D, A versatile alginate droplet generator applicable for microencapsulation of pancreatic islets. J Appl Biomater. 1992; 3: 281-286.
127. Bugarski B, Li Q, Goosen MFA, Electrostatic droplet generation: mechanism of polymer droplet formation. AIChE J. 1994; 40: 1026-1031.
128. Hsu BR, Chen HC, Fu SH, The use of field effects to generate calcium alginate microspheres and its application in cell transplantation. J Formos Med Assoc. 1994; 93: 240-245.
129. De Vos P, De Haan BJ, Van Schilfgaarde R,. Upscaling the production of microencapsulated pancreatic islets. Biomaterials. 1997; 18: 1085-1090.
130. Tendulkar S, Mirmalek-Sani SH, Childers C, A three-dimensional microfluidic approach to scaling up microencapsulation of cells. Biomed Microdevices. 2012; 14: 461-469.
131. Calafiore R,. Transplantation of microencapsulated pancreatic human islets for therapy of diabetes mellitus. A preliminary report. ASAIO J. 1992; 38: 34-37.
132. Petruzzo P, Pibiri L, De Giudici MA, Xenotransplantation of microencapsulated pancreatic islets contained in a vascular prosthesis; preliminary results. Transpl Int. 1991; 4: 200-204.
133. Soon-Shiong P, Heintz RE, Merideth N, Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet. 1994; 343: 950-951.
134. Elliott RB, Escobar L, Tan PL, Live encapsulated porcine islets from type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation. 2007; 14: 157-161.
135. Calafiore R, Basta G, Luca G, Microencapsulated pancreatic islet allograft into non-immunosuppressed patients with Type 1 diabetes. Diabetes Care. 2006; 29: 137-138.
136. Tuch BE, Keogh GW, Williams LJ, Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care. 2009; 32: 1887-1889.
137. Basta G, Montanucci P, Luca G, Long-term metabolic and immunological follow-up of nonimmunosuppressed patients with type 1 diabetes treated with microencapsulated islet allografts: four cases. Diabetes Care. 2011; 34: 2406-2409.
138. Development to Date. Living Cell Technologies Website. 2014. Available at: http://www.lctglobal.com/products/diabecell/development-to-date. Accessed December 29, 2014.
139. Barkai U, Weir GC, Colton CK, Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant. 2013; 22: 1463-1476.
140. Davis NE, Beenken-Rothkopf LN, Mirsoian A, Enhanced function of pancreatic islets co-encapsulated with ECM proteins and mesenchymal stromal cells in a silk hydrogel. Biomaterials. 2012; 33: 6691-6697.
141. Beenken-Rothkopf LN, Karlfeld-Sulzer LS, Davis NE, The incorporation of extracellular matrix proteins in protein polymer hydrogels to improve encapsulated beta-cell function. Ann Clin Lab Sci. 2013; 43: 111-121.
142. Jourdan G, Dusseault J, Benhamou PY, Co-encapsulation of bioengineered IGF-II-producing cells and pancreatic islets: effect on beta-cell survival. Gene Ther. 2011; 18: 539-545.
143. Mehrabi A, Golriz M, Adili-Aghdam F, Expanding the indications of pancreas transplantation alone. Pancreas. 2014; 43: 1190-1193.
144. Bellin MD, Gelrud A, Arreaza-Rubin G, Total pancreatectomy with islet autotransplantation: summary of a National Institute of Diabetes and Digestive and Kidney diseases workshop. Pancreas. 2014; 43: 1163-1171.
145. Irvving-Rodgers HF, Choong FJ, Hummitzsch K, Pancreatic islet basement membrane loss and remodeling after mouse islet isolation and transplantation: impact for allograft rejection. Cell Transplant. 2014; 23: 59-72.
146. Atwater I, Guajardo M, Caviedes P, Isolation of viable porcine islets by selective osmotic shock without enzymatic digestion. Transplant Proc. 2010; 42: 381-386.
147. Taylor MJ, Baicu SC,. Nonenzymatic cryogenic isolation of therapeutic cells: novel approach for enzyme-free isolation of pancreatic islets using in situ cryopreservation of islets and concurrent selective freeze destruction of acinar tissue. Cell Transplant. 2014; 23: 1365-1379.